Table 3.
Quantitative real-time PCR analysis of SCN9A expression in the skin and in the blood.
| Tissue | Sample | Avg Ct SCN9A | Avg Ct GAPDH | ΔCt | ΔΔCt | 2−ΔΔCt | Fold change reduction (−1/2−ΔΔCt) |
|---|---|---|---|---|---|---|---|
| Skin | Proband | 39.61 | 28.03 | 11.58 | 3.73 | 0.08 | −12.5 |
| Mother | 38.66 | 28.15 | 10.51 | 2.66 | 0.16 | −6.25 | |
| HCs (group) | 36.46 | 28.61 | 7.85 | 0 | 1 | — | |
| Blood | Proband | 35.8 | 23.2 | 12.7 | 4.6 | 0.04 | −25 |
| HCs (group) | 32.4 | 24.3 | 8.1 | 0 | 1 | — |
The expression of SCN9A is normalized vs GAPDH housekeeping gene and is calculated as 2−ΔΔCt using as calibrator the aggregated average expression of a group of 2 healthy controls for the skin and 4 healthy controls for the blood. The relative amount of SCN9A is reported as fold change reduction in expression (negative inverse of the 2−ΔΔCt). HCs: healthy controls; Avg Ct: average threshold cycle. Ct values for individual samples are reported in supplementary material, Table S1, http://links.lww.com/PAIN/B534.